HOUSE BILL 343

J3 8lr0725

By: Delegates Kipke, Beitzel, Benson, Bromwell, Costa, Elliott, George, Hammen, Heller, Holmes, Hubbard, Kach, King, Kullen, Love, McDonough, Pena-Melnyk, Reznik, Riley, Robinson, Sophocleus, and Weldon Weldon, Donoghue, Mizeur, Montgomery, Morhaim, Nathan-Pulliam, Oaks, and Pendergrass

Introduced and read first time: January 25, 2008 Assigned to: Health and Government Operations

Committee Report: Favorable with amendments

House action: Adopted

Read second time: March 16, 2008

Γ	H	Δ	PΊ	ΓE	R		

1 AN ACT concerning

 $\mathbf{2}$

3

4

5

6

7

8

9

10 11

12

13

1415

16

17 18

19

20

21

22

Pharmacy Benefits Managers – Prescription Drug Substitution <u>Therapeutic</u> <u>Interchanges</u>

FOR the purpose of prohibiting a pharmacy benefits manager from substituting one prescription drug for the drug originally prescribed or its agent from requesting a therapeutic interchange unless certain conditions are met; requiring a pharmacy benefits manager to disclose certain information to a purchaser if a drug substitution is made; requiring a pharmacy benefits manager or its agent to obtain a certain authorization to make a drug substitution therapeutic interchange and to make certain disclosures to a prescriber; providing for certain exceptions; prohibiting a pharmacy benefits manager from substituting a drug for a currently prescribed drug unless the pharmacy benefits manager provides a beneficiary or the beneficiary's representative with certain information requiring a pharmacy benefits manager or its agent to disclose certain information to a beneficiary and include a certain insert and a certain telephone number with the prescription drug dispensed; requiring a pharmacy benefits manager or its agent to cancel and reverse a therapeutic interchange under certain circumstances; requiring a pharmacy benefits manager or its agent to take certain actions if a therapeutic interchange is reversed; requiring a pharmacy benefits manager to maintain a certain toll-free telephone number; requiring certain disclosures to comply with certain privacy standards; requiring a pharmacy benefits manager to establish certain policies and

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.

<u>Underlining</u> indicates amendments to bill.

Strike out indicates matter stricken from the bill by amendment or deleted from the law by amendment.



$\begin{matrix} 1 \\ 2 \\ 3 \end{matrix}$	procedures; making certain provisions applicable to health maintenance organizations; providing certain penalties; defining certain terms; and generally relating to regulation of pharmacy benefits managers.
4 5	BY adding to Article – Insurance
6	Section 15–1601 and 15–1602 to be under the new subtitle "Subtitle 16.
7	Pharmacy Benefits Managers"
8	Annotated Code of Maryland
9	(2006 Replacement Volume and 2007 Supplement)
10	BY adding to
11	Article – Health – General
12	Section 19–706(ppp)
13	Annotated Code of Maryland
14	(2005 Replacement Volume and 2007 Supplement)
15 16	SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, That the Laws of Maryland read as follows:
17	Article – Insurance
18	SUBTITLE 16. PHARMACY BENEFITS MANAGERS.
19	15–1601.
20	(A) (1) IN THIS SECTION THE FOLLOWING WORDS HAVE THE
21	MEANINGS INDICATED.
	WERNINGS INDICITED:
22	(2) "Beneficiary" means an individual on whose behalf a
23	PURCHASER ENTERS INTO AN AGREEMENT WITH A PHARMACY BENEFITS
24	MANAGER.
25	(2) (1) "DILADMACSY DENIEDING MANAGEMENT GEDYLGEG"
$\frac{25}{26}$	(3) (1) "PHARMACY BENEFITS MANAGEMENT SERVICES"
$\frac{20}{27}$	MEANS THE ADMINISTRATION OR MANAGEMENT OF PRESCRIPTION DRUG
41	BENEFITS.
28	(H) "PHARMACY BENEFITS MANAGEMENT SERVICES"
29	includes:
30	1. PROCUREMENT OF PRESCRIPTION DRUGS AT A
31	NEGOTIATED RATE FOR DISPENSATION WITHIN THE STATE;
32	2. PROCESSING OF PRESCRIPTION DRUG CLAIMS;

1	3. ADMINISTRATION OF PAYMENTS RELATED TO
2	
4	PRESCRIPTION DRUG CLAIMS; AND
3	4. NEGOTIATING OR ENTERING INTO CONTRACTUAL
4	
4	ARRANGEMENTS WITH PHARMACY PROVIDERS.
5	(4) "Pharmacy benefits manager" means a person that
6	PERFORMS PHARMACY BENEFITS MANAGEMENT SERVICES.
U	TENTO TO THE TOTAL OF THE TOTAL
7	(5) (1) "Purchaser" means a person that enters into an
8	AGREEMENT WITH A PHARMACY BENEFITS MANAGER FOR THE PROVISION OF
9	PHARMACY BENEFITS MANAGEMENT SERVICES.
U	THRUME DEVELTED MENTODINE SERVICED
10	(II) "Purchaser" includes the State.
1	(B) THE PROVISIONS OF THIS SECTION DO NOT APPLY TO A MANAGED
12	CARE ORGANIZATION AUTHORIZED BY TITLE 15, SUBTITLE 1 OF THE
13	HEALTH - GENERAL ARTICLE.
L 4	(C) A PHARMACY BENEFITS MANAGER MAY NOT SUBSTITUTE ANOTHER
L 5	PRESCRIPTION DRUG FOR THE CURRENTLY PRESCRIBED PRESCRIPTION DRUG
16	UNLESS:
L 7	(1) THE SUBSTITUTION IS MADE FOR MEDICAL REASONS THAT
l 8	BENEFIT THE BENEFICIARY; OR
	,
L9	(2) THE SUBSTITUTION RESULTS IN FINANCIAL SAVINGS AND
20	BENEFITS TO THE PURCHASER.
21	(D) IF A PRESCRIPTION DRUG SUBSTITUTION IS MADE UNDER THIS
22	SECTION, THE PHARMACY BENEFITS MANAGER SHALL DISCLOSE TO THE
23	PURCHASER ANY BENEFIT OR PAYMENT:
24	(1) RELATED TO THE SUBSTITUTION; AND
25	(2) RECEIVED IN ANY FORM BY THE PHARMACY BENEFITS
26	MANAGER FROM A PHARMACEUTICAL MANUFACTURER OR OTHER PERSON.
27	(E) EXCEPT AS PROVIDED IN SUBSECTIONS (G) AND (H) OF THIS
28	SECTION, A PHARMACY BENEFITS MANAGER SHALL:
29	(1) OBTAIN AUTHORIZATION FROM A PRESCRIBER TO
30	SUBSTITUTE ANOTHER PRESCRIPTION DRUG FOR A CURRENTLY PRESCRIBED
31	PRESCRIPTION DRUG; AND

1	(2) DISCLOSE TO THE PRESCRIBER:
2	(I) THE COST SAVINGS FOR THE PURCHASER, IF ANY, THAT
3	RESULT FROM THE DRUG SUBSTITUTION;
4	(II) THE DIFFERENCE, IF ANY, IN COPAYMENTS OR OTHER
5	OUT-OF-POCKET COSTS PAID BY THE BENEFICIARY TO OBTAIN THE
6	SUBSTITUTE DRUG;
7	(III) THE EXISTENCE OF ADDITIONAL PAYMENTS RECEIVED
8	BY THE PHARMACY BENEFITS MANAGER THAT ARE NOT REFLECTED IN THE
9	COST SAVINGS TO THE PURCHASER;
10	(IV) THE CIRCUMSTANCES, IF ANY, UNDER WHICH THE
11	CURRENTLY PRESCRIBED DRUG WILL BE COVERED;
12	(V) THE CIRCUMSTANCES, IF ANY, AND EXTENT TO WHICH
13	HEALTH CARE COSTS RELATED TO THE DRUG SUBSTITUTION WILL BE
14	COMPENSATED; AND
15	(VI) ANY KNOWN DIFFERENCES IN POTENTIAL EFFECTS ON A
16	BENEFICIARY'S HEALTH AND SAFETY, INCLUDING SIDE EFFECTS.
17	(F) IF AUTHORIZATION IS GIVEN VERBALLY, A PHARMACY BENEFITS
18	MANAGER SHALL RECORD THE NAME AND TITLE OF THE PRESCRIBER
19	AUTHORIZING THE PRESCRIPTION DRUG SUBSTITUTION.
20	(G) SUBSECTION (E) OF THIS SECTION DOES NOT APPLY IF THE
21	SUBSTITUTION IS FROM A BRAND NAME DRUG TO A GENERIC DRUG, AND THE
22	SUBSTITUTION IS MADE IN ACCORDANCE WITH § 12-504 OF THE HEALTH
23	OCCUPATIONS ARTICLE.
24	(H) SUBSECTION (E)(2) OF THIS SECTION DOES NOT APPLY IF:
25	(1) THE CURRENTLY PRESCRIBED DRUG IS NO LONGER
26	AVAILABLE IN THE MARKET; OR
27	(2) THE SUBSTITUTION IS REQUIRED FOR COVERAGE REASONS
28	BECAUSE THE PRESCRIBED DRUG IS NOT COVERED BY THE BENEFICIARY'S
29	FORMULARY OR PLAN.
30	(I) A PHARMACY BENEFITS MANAGER MAY NOT SUBSTITUTE ANOTHER
31	PRESCRIPTION DRUG FOR A CURRENTLY PRESCRIBED PRESCRIPTION DRUG
32	UNLESS THE PHARMACY BENEFITS MANAGER PROVIDES THE BENEFICIARY OR
33	THE BENEFICIARY'S REPRESENTATIVE THE FOLLOWING:

1	(1) UNLESS THE SUBSTITUTION WAS EXEMPTED UNDER
2	SUBSECTION (G) OF THIS SECTION, A NOTIFICATION THAT:
3	(I) THE PHARMACY BENEFITS MANAGER REQUESTED A
4	DRUG SUBSTITUTION BY CONTACTING THE BENEFICIARY'S PRESCRIBER; AND
5	(II) THE PRESCRIBER APPROVED THE DRUG SUBSTITUTION;
6	(2) THE NAMES OF THE PROPOSED DRUG SUBSTITUTION AND THE
7	CURRENTLY PRESCRIBED DRUG;
8	(3) THE DIFFERENCE, IF ANY, IN COPAYMENTS OR OTHER
9	OUT-OF-POCKET COSTS PAID BY THE BENEFICIARY TO OBTAIN THE
10	SUBSTITUTE DRUG;
11	(4) ANY KNOWN DIFFERENCES IN POTENTIAL EFFECTS ON A
12	BENEFICIARY'S HEALTH AND SAFETY, INCLUDING SIDE EFFECTS;
13	(5) THE CIRCUMSTANCES, IF ANY, UNDER WHICH THE
14	CURRENTLY PRESCRIBED DRUG WILL BE COVERED;
15	(6) THE CIRCUMSTANCES, IF ANY, AND THE EXTENT TO WHICH
16	HEALTH CARE COSTS RELATED TO THE DRUG SUBSTITUTION WILL BE
17	COMPENSATED;
18	(7) A NOTIFICATION THAT THE BENEFICIARY MAY DECLINE THE
19	DRUG SUBSTITUTION IF THE CURRENTLY PRESCRIBED DRUG REMAINS ON THE
20	BENEFICIARY'S FORMULARY, AND THE BENEFICIARY IS WILLING TO PAY ANY
21	DIFFERENCE IN THE COPAYMENT AMOUNT; AND
22	(8) A TOLL-FREE TELEPHONE NUMBER TO COMMUNICATE WITH
23	THE PHARMACY BENEFITS MANAGER.
24	(J) (1) A PHARMACY BENEFITS MANAGER SHALL CANCEL AND
25	REVERSE A PRESCRIPTION DRUG SUBSTITUTION ON WRITTEN OR VERBAL
26	INSTRUCTIONS FROM A PRESCRIBER, THE BENEFICIARY, OR THE
27	BENEFICIARY'S REPRESENTATIVE.
28	(2) IF A PRESCRIBER, THE BENEFICIARY, OR THE BENEFICIARY'S
29	REPRESENTATIVE CANCELS AND REVERSES A DRUG SUBSTITUTION, THE
30	PHARMACY BENEFITS MANAGER SHALL:
31	(I) OBTAIN A PRESCRIPTION FOR AND DISPENSE THE

CURRENTLY PRESCRIBED DRUG;

1	(H) CHARGE THE BENEFICIARY ONLY ONE COPAYMENT; AND
2	(III) IF A BENEFICIARY WILL EXHAUST THE SUPPLY OF THE
3	CURRENTLY PRESCRIBED DRUG BEFORE A REPLACEMENT SHIPMENT WILL
4	ARRIVE TO THE BENEFICIARY, ARRANGE FOR DISPENSING OF AN APPROPRIATE
5	QUANTITY OF REPLACEMENT DRUGS AT A RETAIL OR INSTITUTIONAL
6	PHARMACY AT NO ADDITIONAL COST TO THE BENEFICIARY.
7	(3) A PHARMACY BENEFITS MANAGER MAY NOT BE REQUIRED TO
8	CANCEL AND REVERSE A DRUG SUBSTITUTION IF:
9	(I) THE PRESCRIBED DRUG IS NO LONGER ON THE
10	PURCHASER'S FORMULARY; OR
11	(II) A BENEFICIARY IS UNWILLING TO PAY A HIGHER
12	COPAYMENT OR OTHER COST ASSOCIATED WITH THE PRESCRIBED DRUG.
13	(K) A PHARMACY BENEFITS MANAGER SHALL MAINTAIN A TOLL-FREE
14	TELEPHONE NUMBER 24 HOURS A DAY, 7 DAYS A WEEK, FOR PRESCRIBERS,
15	PHARMACY PROVIDERS, AND BENEFICIARIES.
16	(L) ALL DISCLOSURES MADE UNDER THIS SECTION SHALL COMPLY
17	WITH THE PRIVACY STANDARDS OF THE FEDERAL HEALTH INSURANCE
18	PORTABILITY AND ACCOUNTABILITY ACT.
19	(M) ON OR BEFORE APRIL 1, 2009, THE COMMISSIONER SHALL ADOPT
20	REGULATIONS TO IMPLEMENT THIS SECTION.
0.4	
21	(N) (1) THE COMMISSIONER MAY ASSESS A CIVIL PENALTY NOT
22	EXCEEDING \$10,000 FOR EACH VIOLATION OF THIS SECTION.
23	(2) In addition to or instead of assessing a civil penalty,
24	THE COMMISSIONER MAY REQUIRE THE PHARMACY BENEFITS MANAGER TO
25	MAKE RESTITUTION TO ANY PERSON WHO HAS SUFFERED FINANCIAL INJURY
26	BECAUSE OF THE VIOLATION OF THIS SECTION.
27	<u>15–1601.</u>
28	(A) IN THIS SUBTITLE THE FOLLOWING WORDS HAVE THE MEANINGS
29	INDICATED.
30	(B) "AGENT" MEANS A PHARMACY, A PHARMACIST, A MAIL ORDER
31	PHARMACY, OR A NONRESIDENT PHARMACY ACTING ON BEHALF OR AT THE

DIRECTION OF A PHARMACY BENEFITS MANAGER.

1	(C) "BENEFICIARY" MEANS AN INDIVIDUAL WHO RECEIVES
$\overline{2}$	PRESCRIPTION DRUG COVERAGE OR BENEFITS FROM A PURCHASER.
3	(D) "ERISA" HAS THE MEANING STATED IN § 8–301 OF THIS ARTICLE.
4	(E) "NONPROFIT HEALTH MAINTENANCE ORGANIZATION" HAS THE
5	(E) "NONPROFIT HEALTH MAINTENANCE ORGANIZATION" HAS THE MEANING STATED IN § 6–121(A) OF THIS ARTICLE.
J	MARING STITLE IN 3 V 121(II) OF THIS INVITCING
6	(F) "NONRESIDENT PHARMACY" HAS THE MEANING STATED IN § 12–403
7	OF THE HEALTH OCCUPATIONS ARTICLE.
8	(G) "PHARMACIST" HAS THE MEANING STATED IN § 12-101 OF THE
9	HEALTH OCCUPATIONS ARTICLE.
	ATTACHE THE THE TACKET
10	(H) "PHARMACY" HAS THE MEANING STATED IN § 12–101 OF THE
11	HEALTH OCCUPATIONS ARTICLE.
12	(I) (1) "PHARMACY BENEFITS MANAGEMENT SERVICES" MEANS:
14	(I) (I) FHARMACI BENEFII'S MANAGEMENT SERVICES MEANS:
13	(I) THE PROCUREMENT OF PRESCRIPTION DRUGS AT A
14	NEGOTIATED RATE FOR DISPENSATION WITHIN THE STATE TO BENEFICIARIES;
1 5	
15 16	(II) THE ADMINISTRATION OR MANAGEMENT OF PRESCRIPTION DRUG COVERAGE PROVIDED BY A PURCHASER FOR
17	PRESCRIPTION DRUG COVERAGE PROVIDED BY A PURCHASER FOR BENEFICIARIES; AND
	
18	(III) ANY OF THE FOLLOWING SERVICES PROVIDED WITH
19	REGARD TO THE ADMINISTRATION OF PRESCRIPTION DRUG COVERAGE:
20	1. MAIL SERVICE PHARMACY;
20	i. MAIL SERVICE FITARWACT,
21	2. CLAIMS PROCESSING, RETAIL NETWORK
22	MANAGEMENT, AND PAYMENT OF CLAIMS TO PHARMACIES FOR PRESCRIPTION
23	DRUGS DISPENSED TO BENEFICIARIES;
24	3. CLINICAL FORMULARY DEVELOPMENT AND
25	MANAGEMENT SERVICES;
26	4. REBATE CONTRACTING AND ADMINISTRATION;
27	
28	5. PATIENT COMPLIANCE, THERAPEUTIC INTERVENTION, AND GENERIC SUBSTITUTION PROGRAMS; OR
	INTERVENTION, AND GENERIC SUBSTITUTION I ROURANS, OR
29	6. DISEASE MANAGEMENT PROGRAMS.

DISEASE MANAGEMENT PROGRAMS.

<u>6.</u>

<u>(2)</u>

1	(2) "PHARMACY BENEFITS MANAGEMENT SERVICES" DOES NOT
2	INCLUDE ANY SERVICE PROVIDED BY A NONPROFIT HEALTH MAINTENANCE
3	ORGANIZATION THAT OPERATES AS A GROUP MODEL, PROVIDED THAT THE
4	SERVICE:
5	(I) IS PROVIDED SOLELY TO A MEMBER OF THE NONPROFIT
6	HEALTH MAINTENANCE ORGANIZATION; AND
7	(II) IS FURNISHED THROUGH THE INTERNAL PHARMACY
8	OPERATIONS OF THE NONPROFIT HEALTH MAINTENANCE ORGANIZATION.
9	(J) "PHARMACY BENEFITS MANAGER" MEANS A PERSON THAT
10	PERFORMS PHARMACY BENEFITS MANAGEMENT SERVICES.
11	(K) "PHARMACY AND THERAPEUTICS COMMITTEE" MEANS A
12	COMMITTEE ESTABLISHED BY A PHARMACY BENEFITS MANAGER TO:
13	(1) OBJECTIVELY APPRAISE AND EVALUATE PRESCRIPTION
14	DRUGS; AND
1 =	
15 16	(2) MAKE RECOMMENDATIONS TO A PURCHASER REGARDING THE
16	SELECTION OF DRUGS FOR THE PURCHASER'S FORMULARY.
17	(L) (1) "PURCHASER" MEANS THE STATE EMPLOYEE AND RETIRES
18	
19	HEALTH AND WELFARE BENEFITS PROGRAM, AN INSURER, A NONPROFIT HEALTH SERVICE PLAN, OR A HEALTH MAINTENANCE ORGANIZATION THAT:
13	HEALTH SERVICE PLAN, OR A HEALTH MAINTENANCE ORGANIZATION THAT:
20	(I) PROVIDES PRESCRIPTION DRUG COVERAGE OF
21	BENEFITS IN THE STATE; AND
	DENEFITS IN THE STATE, AND
22	(II) ENTERS INTO AN AGREEMENT WITH A PHARMACY
23	BENEFITS MANAGER FOR THE PROVISION OF PHARMACY BENEFITS
24	MANAGEMENT SERVICES.
	WHITE SELVICES.
25	(2) "PURCHASER" DOES NOT INCLUDE A PERSON THAT PROVIDES
26	PRESCRIPTION DRUG COVERAGE OR BENEFITS THROUGH PLANS SUBJECT TO
27	ERISA AND DOES NOT PROVIDE PRESCRIPTION DRUG COVERAGE OR BENEFITS
28	THROUGH INSURANCE, UNLESS THE PERSON IS A MULTIPLE EMPLOYER
29	WELFARE ASSOCIATION AS DEFINED IN § 514(B)(6)(A)(II) OF ERISA.
30	(M) (1) "THERAPEUTIC INTERCHANGE" MEANS ANY CHANGE FROM
31	ONE PRESCRIPTION DRUG TO ANOTHER.

"THERAPEUTIC INTERCHANGE" DOES NOT INCLUDE:

1	(I) A CHANGE INITIATED PURSUANT TO A DRUG
2	UTILIZATION REVIEW;
3	(II) A CHANGE INITIATED FOR PATIENT SAFETY REASONS;
4	(III) A CHANGE REQUIRED DUE TO MARKET UNAVAILABILITY
5	OF THE CURRENTLY PRESCRIBED DRUG;
6	(IV) A CHANGE FROM A BRAND NAME DRUG TO A GENERIC
7	DRUG IN ACCORDANCE WITH § 12–504 OF THE HEALTH OCCUPATIONS
8	ARTICLE; OR
0	
9 10	(V) A CHANGE REQUIRED FOR COVERAGE REASONS
11	BECAUSE THE ORIGINALLY PRESCRIBED DRUG IS NOT COVERED BY THE BENEFICIARY'S FORMULARY OR PLAN.
	BENEFICIAL STORMOMENT OUT EAST
12	(N) "THERAPEUTIC INTERCHANGE SOLICITATION" MEANS ANY
13	COMMUNICATION BY A PHARMACY BENEFITS MANAGER FOR THE PURPOSE OF
14	REQUESTING A THERAPEUTIC INTERCHANGE.
15	<u>15–1602.</u>
16	(A) A PHARMACY BENEFITS MANAGER OR ITS AGENT MAY NOT REQUEST
17	A THERAPEUTIC INTERCHANGE UNLESS:
18	(1)
10 19	(1) THE PROPOSED THERAPEUTIC INTERCHANGE IS FOR MEDICAL REASONS THAT BENEFIT THE BENEFICIARY; OR
	MEDICAL REASONS THAT BENEFIT THE BENEFICIART, OR
20	(2) THE PROPOSED THERAPEUTIC INTERCHANGE WILL RESULT IN
21	FINANCIAL SAVINGS AND BENEFITS TO THE PURCHASER OR THE BENEFICIARY.
22	(B) (1) BEFORE MAKING A THERAPEUTIC INTERCHANGE, A
23	PHARMACY BENEFITS MANAGER OR ITS AGENT SHALL OBTAIN AUTHORIZATION
24	FROM A PRESCRIBER OR AN INDIVIDUAL AUTHORIZED BY THE PRESCRIBER.
25 26	(C) IN ANY THERAPEUTIC INTERCHANGE SOLICITATION, THE
26	FOLLOWING SHALL BE DISCLOSED TO THE PRESCRIBER:
27	(1) THAT A THERAPEUTIC INTERCHANGE IS BEING SOLICITED;
28	(2) THE CIRCUMSTANCES UNDER WHICH THE ORIGINALLY
29	PRESCRIBED DRUG WILL BE COVERED BY THE PURCHASER;

1	(3) THE DIFFERENCE IN COPAYMENTS OR COINSURANCE TO BE
2	PAID BY THE BENEFICIARY TO OBTAIN THE PROPOSED DRUG;
_	
3	(4) THE CIRCUMSTANCES AND EXTENT TO WHICH HEALTH CARE
4	COSTS RELATED TO THE THERAPEUTIC INTERCHANGE WILL BE COMPENSATED;
5	<u>AND</u>
6	(5) ANY CLINICALLY SIGNIFICANT DIFFERENCES, AS
7	DETERMINED BY A PHARMACY AND THERAPEUTICS COMMITTEE OF THE
8	PHARMACY BENEFITS MANAGER, WITH RESPECT TO EFFICACY, SIDE EFFECTS,
9	AND POTENTIAL IMPACT ON HEALTH AND SAFETY.
10	(D) WHEN SOLICITING A THERAPEUTIC INTERCHANGE FROM A
11	PRESCRIBER, A PHARMACY BENEFITS MANAGER OR ITS AGENT MAY NOT MAKE A
12	CLAIM THAT THE THERAPEUTIC INTERCHANGE WILL SAVE THE PURCHASER
13	MONEY UNLESS THE CLAIM CAN BE SUBSTANTIATED.
14	(E) IF THE PHARMACY BENEFITS MANAGER OR ITS AGENT RECEIVES
15	PAYMENT FOR MAKING A THERAPEUTIC INTERCHANGE FROM A
16	PHARMACEUTICAL MANUFACTURER OR OTHER PERSON, INCLUDING THE
17	PHARMACY BENEFITS MANAGER, THAT IS NOT REFLECTED IN COST SAVINGS TO
18	THE PURCHASER, THE EXISTENCE OF THE PAYMENT SHALL BE COMMUNICATED
19	TO THE PRESCRIBER AT THE TIME OF THE THERAPEUTIC INTERCHANGE
20	SOLICITATION.
21	(F) IF A THERAPEUTIC INTERCHANGE OCCURS, THE PHARMACY
22	BENEFITS MANAGER OR ITS AGENT SHALL:
ດວ	(1) Progressor to the province by an array on the worthing.
23	(1) <u>DISCLOSE TO THE BENEFICIARY, ORALLY OR IN WRITING:</u>
24	(I) THAT THE PHARMACY BENEFITS MANAGER OR ITS
25	AGENT REQUESTED A THERAPEUTIC INTERCHANGE BY CONTACTING THE
26	BENEFICIARY'S PRESCRIBER;
	
27	(II) THE PRESCRIBER APPROVED THE THERAPEUTIC
28	INTERCHANGE;
29	(III) THE NAMES OF THE ORIGINALLY PRESCRIBED DRUG
30	AND THE DRUG DISPENSED PURSUANT TO THE THERAPEUTIC INTERCHANGE;
31	(IV) THE DIBERDENCE IN CODAVIDATION OF COINCIDANCE TO
$\frac{31}{32}$	(IV) THE DIFFERENCE IN COPAYMENTS OR COINSURANCE TO BE PAID BY THE BENEFICIARY TO OBTAIN THE DRUG DISPENSED PURSUANT TO
33	THE THERAPEUTIC INTERCHANGE;

1	(V) THE CIRCUMSTANCES UNDER WHICH THE ORIGINALLY
2	PRESCRIBED DRUG WILL BE COVERED;
9	
$\frac{3}{4}$	(VI) THE CIRCUMSTANCES UNDER AND THE EXTENT TO
5	WHICH HEALTH CARE COSTS RELATED TO THE THERAPEUTIC INTERCHANGE
Э	WILL BE COMPENSATED; AND
6	(VII) THAT THE BENEFICIARY MAY DECLINE THE
7	THERAPEUTIC INTERCHANGE IF THE ORIGINALLY PRESCRIBED DRUG REMAINS
8	ON THE BENEFICIARY'S FORMULARY, AND THE BENEFICIARY IS WILLING TO PAY
9	ANY DIFFERENCE IN THE COPAYMENT OR COINSURANCE; AND
10	(2) INCLUDE WITH THE PRESCRIPTION DRUG DISPENSED:
10	(2) INCLUDE WITH THE PRESCRIPTION DRUG DISPENSED:
11	(I) A PATIENT PACKAGE INSERT ABOUT POTENTIAL SIDE
12	EFFECTS; AND
10	
13	(II) A TOLL-FREE TELEPHONE NUMBER TO COMMUNICATE
14	WITH THE PHARMACY BENEFITS MANAGER.
15	(G) (1) A PHARMACY BENEFITS MANAGER OR ITS AGENT SHALL
16	CANCEL AND REVERSE A THERAPEUTIC INTERCHANGE ON WRITTEN OR VERBAL
17	INSTRUCTIONS FROM A PRESCRIBER, THE BENEFICIARY, OR THE
18	BENEFICIARY'S REPRESENTATIVE.
19	(0) In a supplying nymphoning is prymphone supp
	(2) If a therapeutic interchange is reversed, the
20	PHARMACY BENEFITS MANAGER OR ITS AGENT SHALL:
21	(I) OBTAIN A PRESCRIPTION FOR AND DISPENSE THE
22	ORIGINALLY PRESCRIBED PRESCRIPTION DRUG; AND
ດດ	(77) 677.17.67 7777 77777777777 110 110 110 170 170 1
23	(II) CHARGE THE BENEFICIARY NO MORE THAN ONE
24	COPAYMENT.
25	(3) If the therapeutic interchange occurred through a
26	MAIL ORDER PHARMACY AND A BENEFICIARY WILL EXHAUST AN EXISTING
27	SUPPLY OF THE ORIGINALLY PRESCRIBED PRESCRIPTION DRUG BEFORE A
28	REPLACEMENT SHIPMENT WILL ARRIVE TO THE BENEFICIARY, THE PHARMACY
29	BENEFITS MANAGER OR ITS AGENT SHALL ARRANGE FOR DISPENSING OF AN
30	APPROPRIATE QUANTITY OF REPLACEMENT PRESCRIPTION DRUGS AT A LOCAL
31	COMMUNITY PHARMACY AT NO ADDITIONAL COST TO THE BENEFICIARY.
32	(4) A DITADMACK DENIEDIZE MANACED OD IZE A CENTE MASK NOTE DE
υZ	(4) A PHARMACY BENEFITS MANAGER OR ITS AGENT MAY NOT BE

REQUIRED TO CANCEL AND REVERSE A THERAPEUTIC INTERCHANGE IF A

33

25

October 1, 2008.

	12 HOUSE BILL 343
1	BENEFICIARY IS UNWILLING TO PAY A HIGHER COPAYMENT OR COINSURANCE
2	ASSOCIATED WITH THE ORIGINALLY PRESCRIBED PRESCRIPTION DRUG.
3	(H) (1) A PHARMACY BENEFITS MANAGER SHALL MAINTAIN A
$\frac{3}{4}$	
	TOLL-FREE TELEPHONE NUMBER MONDAY THROUGH SATURDAY FOR
5	PRESCRIBERS, PHARMACIES, PHARMACISTS, AND BENEFICIARIES TO REQUEST
6	INFORMATION REGARDING A THERAPEUTIC INTERCHANGE.
_	
7	(2) THE TOLL-FREE TELEPHONE NUMBER SHALL BE ACCESSIBLE
8	FROM 8 A.M. UNTIL AT LEAST 8 P.M. EASTERN STANDARD TIME.
9	(I) ALL DISCLOSURES MADE UNDER THIS SECTION SHALL COMPLY
10	WITH THE PRIVACY STANDARDS SET FORTH IN STATE AND FEDERAL LAW.
11	(J) A PHARMACY BENEFITS MANAGER SHALL ESTABLISH APPROPRIATE
12	POLICIES AND PROCEDURES TO IMPLEMENT THE REQUIREMENTS OF THIS
13	SECTION.
	<u>========</u>
14	(K) (1) THE COMMISSIONER MAY ASSESS A CIVIL PENALTY NOT
15	EXCEEDING \$10,000 FOR EACH VIOLATION OF THIS SECTION.
10	EXCEPTING \$10,000 FOR EXCIT VIOLATION OF THIS SECTION.
16	(2) IN ADDITION TO OR INSTEAD OF ASSESSING A CIVIL PENALTY
17	THE COMMISSIONER MAY REQUIRE THE PHARMACY BENEFITS MANAGER TO
18	•
	MAKE RESTITUTION TO ANY PERSON THAT HAS SUFFERED FINANCIAL INJURY
19	BECAUSE OF A VIOLATION OF THIS SECTION.
00	
20	<u> Article - Health - General</u>
01	10 500
21	<u>19–706.</u>
00	(nnn)
22	(PPP) THE PROVISIONS OF TITLE 15, SUBTITLE 16 OF THE INSURANCE
23	ARTICLE APPLY TO HEALTH MAINTENANCE ORGANIZATIONS.

SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect